An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis

Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis

(2022) Xi Chen et al.   CURRENT MICROBIOLOGY

Development of 6-Methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents

(2022) Rui Shi et al.   ACS Medicinal Chemistry Letters

QcrB in Mycobacterium tuberculosis : The new drug target of antitubercular agents

(2021) Aparna Bahuguna et al.   MEDICINAL RESEARCH REVIEWS

Synthetic molecules as DprE1 inhibitors: A patent review

(2021) Mohd. Imran et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts

(2021) Jeremiah Chakaya et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Synthesis and recycling of the mycobacterial cell envelope

(2021) Katherine A Abrahams et al.   CURRENT OPINION IN MICROBIOLOGY

Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832

(2021) Gregory T. Robertson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

(2021) Mohd. Imran et al.   Journal of Infection and Public Health

Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence

(2021) Sonali Chhabra et al.   ACS Omega

Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

(2021) Mohd. Imran et al.   Pharmaceuticals

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

(2021) Mohd. Imran et al.   MOLECULES

Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy

(2021) Wenping Gong et al.   Frontiers in Microbiology

New tuberculosis drug targets, their inhibitors, and potential therapeutic impact

(2020) Gauri S. Shetye et al.   Translational Research

Development of Macozinone for TB treatment: An Update

(2020) Vadim Makarov et al.   Applied Sciences-Basel

Diagnostic Potential of IgG and IgA Responses to Mycobacterium tuberculosis Antigens for Discrimination among Active Tuberculosis, Latent Tuberculosis Infection, and Non-Infected Individuals

(2020) Ji Yeon Lee et al.   Microorganisms

Macozinone: revised synthesis and crystal structure of a promising new drug for treating drug-sensitive and drug-resistant tuberculosis

(2019) Gang Zhang et al.   Acta Crystallographica Section C-Structural Chemistry

A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis

(2019) Karen Cohen et al.   Expert Opinion On Drug Safety

Pretomanid: First Approval

(2019) Susan J. Keam   DRUGS

Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development

(2019) Tiago Beites et al.   Nature Communications

Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis

(2018) Jérémie Piton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug targets exploited in Mycobacterium tuberculosis : Pitfalls and promises on the horizon

(2018) Zubair Shanib Bhat et al.   BIOMEDICINE & PHARMACOTHERAPY

Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1): challenging target for antitubercular drug discovery

(2018) Jineetkumar Gawad et al.   Chemistry Central Journal

Drug discovery in tuberculosis. New drug targets and antimycobacterial agents

(2018) André Campaniço et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Expanding Benzoxazole-Based Inosine 5′-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure–Activity As Potential Antituberculosis Agents

(2018) Shibin Chacko et al.   JOURNAL OF MEDICINAL CHEMISTRY

Central Nervous System Tuberculosis

(2018) Martin Alexander Schaller et al.   Clinical Neuroradiology

Tuberculosis treatment

(2017) Marcelo Fouad Rabahi et al.   Jornal Brasileiro de Pneumologia

A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells

(2017) Paridhi Sukheja et al.   mBio

Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions

(2017) Tiansheng Wang et al.   ACS Medicinal Chemistry Letters

New agents for the treatment of drug-resistant Mycobacterium tuberculosis

(2016) Daniel T. Hoagland et al.   ADVANCED DRUG DELIVERY REVIEWS

Exploring the structure of glutamate racemase from Mycobacterium tuberculosis as a template for anti-mycobacterial drug discovery

(2016) S. Poen et al.   BIOCHEMICAL JOURNAL

Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ

(2016) Krupanandan Haranahalli et al.   BIOORGANIC & MEDICINAL CHEMISTRY

A Target-Based Whole Cell Screen Approach To Identify Potential Inhibitors of Mycobacterium tuberculosis Signal Peptidase

(2016) Shilah A. Bonnett et al.   ACS Infectious Diseases

Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis

(2015) Benoit Lechartier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Traitement de la tuberculose

(2015) J. Ben Amar et al.   Revue de Pneumologie Clinique

DprE1 - from the Discovery to the Promising Tuberculosis Drug Target

(2014) Katarina Miku.sova et al.   CURRENT PHARMACEUTICAL DESIGN

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

(2014) V. Makarov et al.   EMBO Molecular Medicine

The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis

(2013) Giovanna Riccardi et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Structural Basis for the Recognition of Mycolic Acid Precursors by KasA, a Condensing Enzyme and Drug Target fromMycobacterium Tuberculosis

(2013) Johannes Schiebel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis

(2013) Regina Wilson et al.   Nature Chemical Biology

Treatment of latent tuberculosis infection

(2013) Madhavi J. Parekh et al.   Therapeutic Advances in Respiratory Disease

RETRACTED ARTICLE: Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase DprE1: state of art

(2012) Silvia Buroni et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis

(2012) Myungsun Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones

(2010) M. R. Pasca et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel targets in M. tuberculosis: search for new drugs

(2010) Gyanu Lamichhane   TRENDS IN MOLECULAR MEDICINE

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

(2009) V. Makarov et al.   SCIENCE